Key Highlights
- Definium Therapeutics stock climbed approximately 52% on June 22, 2026, following positive Phase 3 Emerge trial results for DT120 in treating major depressive disorder
- The treatment achieved an 8.1-point improvement versus placebo on the MADRS scale by Week 6, with patients experiencing benefits starting at Week 1
- Safety data proved favorable — approximately 99% of adverse events were classified as mild to moderate, with no emerging safety concerns or elevated suicidality risk
- The company maintains approximately $411.6 million in cash reserves with no immediate financing requirements, and DT120 has received FDA Breakthrough Therapy Designation
- Several major financial institutions including Jefferies, RBC Capital, and Canaccord Genuity maintain Buy recommendations; one analyst established a $44 price objective in early June
Definium Therapeutics (DFTX) stock experienced a dramatic surge of up to 52% on Monday following the announcement that its Phase 3 Emerge clinical trial for DT120 successfully achieved its primary endpoint in major depressive disorder treatment.
Prior to market opening, shares had already climbed approximately 39% to reach $34.01. During midday trading, the stock extended its gains, crossing $37 — significantly exceeding its previous 52-week peak of $26.25.
The clinical study recruited adult participants diagnosed with major depressive disorder and evaluated a single 100 microgram oral dose of DT120, the company’s proprietary tablet formulation containing lysergide (LSD). The trial successfully achieved its primary objective, demonstrating an 8.1-point placebo-adjusted improvement measured by the Montgomery-Åsberg Depression Rating Scale at the six-week mark.
This outcome achieved statistical significance with a p-value under 0.0001. Participants began experiencing therapeutic benefits as early as Week 1, with sustained improvements maintained through Week 12.
Secondary endpoints corroborated the primary findings, including Clinical Global Impressions severity measurements, which similarly demonstrated positive outcomes.
Regarding safety, the profile appeared exceptionally clean. Approximately 99% of treatment-related adverse events were categorized as mild to moderate in severity, discontinuation rates remained comparable to the placebo group, and no novel safety signals emerged. Critically, there was no elevation in suicidality — a significant concern within this therapeutic category.
Wall Street Support Already Established
Definium entered this data readout with substantial analyst backing. Jefferies, RBC Capital, Canaccord Genuity, and LifeSci Capital had all reaffirmed Buy ratings during the weeks preceding the announcement.
Analyst Francois Brisebois elevated his price target to $44 in early June, highlighting a “de-risked” investment opportunity for DT120 across both anxiety and depression indications. The most current analyst consensus maintains a Buy rating with a $38 price objective.
The biotech company also approaches this critical milestone with robust financial positioning. Definium reported approximately $411.6 million in cash holdings according to its most recent disclosure, eliminating near-term capital concerns. This financial runway is projected to extend operations through 2028.
DT120 has also secured FDA Breakthrough Therapy Designation, potentially accelerating the regulatory review process toward submission.
The Road Ahead
Definium currently has a second Phase 3 study in progress named Ascend, which mirrors the design of the Emerge trial. With one successful positive readout now confirmed, the company has strengthened its foundation for an eventual New Drug Application submission targeting major depressive disorder.
Competitor Compass Pathways (CMPS) also experienced upward price movement during the same trading session, indicating that the Emerge results bolstered investor confidence throughout the psychedelic therapeutics sector.
The broader equity markets provided a supportive backdrop as well, with the Nasdaq advancing 1.9% and the S&P 500 gaining 1.1%.
Following this substantial price movement, Definium’s current market capitalization stands at approximately $2.67 billion.
